問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Radiology

Division of Obstetrics & Gynecology

更新時間：2025-10-20

林吉晉Lin, Gigin
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

  • giginlin@cgmh.org.tw

Recruiting Trial

23Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林吉晉

List

29Cases

2022-05-01 - 2025-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-11-16 - 2026-03-31

Phase III

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).

  • Condition/Disease

    Endometrial Cancer

  • Test Drug

    pembrolizumab

Participate Sites
5Sites

Not yet recruiting5Sites

2023-11-01 - 2026-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-01-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2014-05-21 - 2017-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-01-01 - 2019-12-31

Others

Molecular PET/MR imaging in vivo validation of biomarker for human prostate cancer

  • Condition/Disease

    Prostate Adenocarcinoma

  • Test Drug

    [11C]Choline ([11C]Methyl-dimethyl-2-hydroxyethyl-ammonium), Glass vial with 40-331mCi of 11C choline in aqueous 0.9% sodium

Participate Sites
1Sites

Recruiting1Sites

2021-05-07 - 2023-06-15

Phase I

A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    AMG 650

Participate Sites
3Sites

Recruiting3Sites

2017-09-21 - 2021-10-14

Phase III

A Randomized, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids

  • Condition/Disease

    Uterine Fibroids

  • Test Drug

    Vilaprisan (BAY 1002670)

Participate Sites
8Sites

Terminated8Sites

2021-03-01 - 2023-07-31

Phase II

Precision Medicine Imaging for Cervical Cancer: Integrating MR Fingerprinting, Dynamic Nuclear Polarization (DNP)-MRI and Artificial Intelligence Radiomics

  • Condition/Disease

    Cervical Cancer

  • Test Drug

    Hyperpolarized [1-13C]Pyruvate

Participate Sites
1Sites

Recruiting1Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB